Many small biotech players have put the foot on the gas in 2020. With the urgent need for a COVID-19 vaccine and treatment still the number one global priority, this comes as no surprise.Athersys (ATHX) is among those to rise to the challenge and the market has rewarded the micro-cap accordingly. Shares have appreciated by 114% since the turn of the year.Yet, Dawson James analyst Jason Kolbert believes the upward movement has a long way to go.Kolbert reiterated a Buy rating on ATHX shares along with a $12 price target. Investors can expect returns of a whopping 360%, should the …read more
Source:: Yahoo Finance
